栀子抗抑郁方治疗糖尿病患者抑郁的系统评价与Meta分析
该系统评价与Meta分析纳入12项RCT共822例糖尿病合并抑郁患者,评估栀子抗抑郁方(GFAF)的疗效与安全性。结果显示GFAF单用或联合SSRI可显著降低HAMD和SDS评分,但需更多大样本高质量RCT验证。
要点
- GFAF单用或联合SSRI可降低糖尿病合并抑郁患者的HAMD评分。
- GFAF单用较SSRI单用HAMD评分更低,联合SSRI优于SSRI单用。
- SDS评分变化与HAMD一致,但证据受纳入研究质量限制。
核心结论
- GFAF可能作为糖尿病患者抑郁的替代治疗,但需更多大规模、设计良好的RCT验证。
研究设计与样本
- 系统评价与Meta分析纳入12项RCT,共822例糖尿病合并抑郁患者,检索至2019年5月。
主要发现
- 与无抗抑郁治疗相比,GFAF治疗显著降低HAMD评分(SMD: -2.53, 95% CI: -4.80 to -0.27, P = 0.03)。
- GFAF单用较SSRI单用HAMD评分更低(SMD: -0.62, 95% CI: -1.07 to -0.18, P = 0.006)。
- GFAF联合SSRI较SSRI单用HAMD评分显著降低(SMD: -0.37, 95% CI: -0.69 to -0.06, P = 0.02)。
- SDS评分变化与HAMD评分呈现相同模式。
临床怎么用
- 在糖尿病合并抑郁患者中,可考虑使用GFAF单用或联合SSRI以改善抑郁评分。
局限性
- 需要更多大规模、设计良好的RCT进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Diabetes is closely related with depression. Gardenia fructus antidepressant formula (GFAF) is a Chinese herbal medicine that may be beneficial for depression in diabetic patients. This study aimed to evaluate the efficacy and safety of GFAF for depression in diabetes patients. METHODS: Randomized controlled trials (RCTs) were included. The patients were diagnosed as having diabetes mellitus with depression. The experimental interventions included GFAF alone or combined with another active treatment. The control interventions included no treatment, placebo or another active treatment. The primary outcome was reduction in the Hamilton Depression Scale (HAMD) scores. Secondary outcomes included reduction in the Self-rating Depression Scale (SDS) scores, response rate, adverse events, etc. PubMed, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wan fang database and Chinese Science and Technology Periodicals database (VIP) were searched from inception to May 2019 for potentially eligible studies. The meta-analysis was performed using RevMan 5.3 software. RESULTS: We identified 12 eligible RCTs including 822 diabetes patients with depression. Results of meta-analysis showed that the HAMD score was significantly reduced following GFAF treatment compared with no antidepressant treatment (SMD: -2.53, 95% CI: -4.80 to -0.27, P = 0.03). Another meta-analysis indicated that patients taking GFAF alone had lower HAMD scores compared with selective serotonin reuptake inhibitors (SSRI) treatment alone (SMD: -0.62, 95% CI: -1.07 to -0.18, P = 0.006). The HAMD scores in the GFAF plus SSRI treatment group were significantly decreased compared with the SSRI treatment group (SMD: -0.37, 95% CI: -0.69 to -0.06, P = 0.02). The same pattern of change was identified with the SDS scores. CONCLUSION: GFAF may be considered an alternative treatment for depression in patients with diabetes. However, more large-scale and well-designed RCTs are warranted.
引用
- Li KD, Wang QS, Zhang WW, et al. Gardenia fructus antidepressant formula for depression in diabetes patients: A systematic review and meta-analysis. Complement Ther Med. 2019. PMID: 31987254. doi:10.1016/j.ctim.2019.102248
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。